In the second part of this podcast, haematologist and clinical researcher Dr Phillip Thompson talks about the rapidly evolving area of treatment for relapsed/refractory CLL after chemo-immunotherapy.

Dr Thompson  says it is important to re-evaluate a person’s genomic characteristics after a relapse and the overall approach is to use novel agents rather than repeat chemo-immunotherapy.

He describes the latest evidence of survival benefits with novel agents in R/R CLL.  Dr Thompson also talks about two exciting new lines of research in Richter’s transformation where spectacular response rates have been achieved with some agents.

Part 1 of the podcast is on treatment in front-line CLL

PLEASE REVIEW PRODUCT INFORMATION BEFORE PRESCRIBING (available from www.janssen.com.au/imbruvica_PI).